ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and …MarketWatch (press release)Phase II trials are now in process that evaluate SAR3419: (1) as a single agent for diffuse large B-cell lymphoma (DLBCL); (2) in combination wi…

NICE final OK extends use of MabTheraPharma TimesThe National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Roche's MabThera (rituximab) as an option when used in combination with a wide range of chemoth…

Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®Business Wire (press release)Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated…

Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN(R)MarketWatch (press release)Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated …

Approval of first-ever medicine for rare blood vessels diseases offers hope …Canada NewsWire (press release)1 Today, Roche announced that RITUXAN ® (rituximab), in combination with glucocorticoids, is the first medicine approved by Health Canada for…

UK's NICE Clears Roche Drug For Use In Follicular LymphomaCapital.gr (press release)The decision confirms draft guidance issued last May and follows months of consideration by the National Institute for Health and Clinical Excellence, which has now…

Spectrum reports encouraging results from ZEVALIN studyPharmaceutical Business ReviewThe standard-dose ibritumomab tiuxetan combined with BEAM high-dose chemotherapy is safe and effective than BEAM alone as conditioning regimen for ASCT in the era of r…

Severe High-Density Lipoprotein Deficiency Associated With Autoantibodies …Archives of Internal MedicineOn July 2007, treatment started with 3 cycles of cyclophosphamide, hydroxyldaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (CHOP…

ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive …MarketWatch (press release)In the era of rituximab-containing frontline regimens, it is becoming more challenging to salvage patients with ASCT in this setting, and novel ap…

Sandoz Initiates Two More Phase III Biosimilar Trials, Reinforcing Long-term …VAdvert Press Center (press release)Ameet Mallik, global head of Sandoz Biopharmaceuticals, added: “The start of these two studies represents significant progress for our…